We began by first selecting a well-characterized downstream target of the PI3K-Akt pathway, phospho-p70s6k (T389), to verify pathway activation at our infection conditions of interest and to ensure that the pathway would respond appropriately to manipulation by the small molecule inhibitor we planned to use in our subsequent studies (LY294002). Here, RPS6KB1 is linked to infection.